bioAffinity Technologies, Inc. announced on August 7, 2025, a significant surge in commercial sales of its flagship product, CyPath® Lung. The company reported that completed tests in July represented a 72% increase over the previous monthly average for the first six months of 2025.
This upward trend reflects back-to-back record monthly sales in June and July, indicating accelerating adoption and trust in the technology. The company reaffirmed its forecast of 3X year-over-year revenues for CyPath® Lung.
The success of a pilot marketing program in Texas, which accounts for approximately 6% of U.S. pulmonologists, has demonstrated the effectiveness of the company's approach to the medical community. This commercial momentum is expected to support long-term revenue growth as bioAffinity Technologies expands into additional key markets, including the Mid-Atlantic region and the Veterans Administration healthcare system.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.